Hengrui Medicine: Subsidiary drug RSS0393 Latex approved for clinical trials.

Hengrui Pharmaceuticals announced that its subsidiary Ruishi Biopharmaceutical Co., Ltd. has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for latex RSS0393, and will soon conduct clinical trials for the treatment of atopic dermatitis. The product is a latex containing a small molecule inhibitor of PDE4, with a total research and development investment of approximately 53 million yuan. The drug research and development cycle is long and complex, with uncertainties. The company will continue to advance the project and disclose progress in a timely manner.